KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Current Leases (2019 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Current Leases for 7 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 11.91% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 11.91% increase, with the full-year FY2025 number at $1.5 million, up 11.91% from a year prior.
  • Current Leases was $1.5 million for Q4 2025 at Xenon Pharmaceuticals, up from $1.5 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.5 million in Q4 2025 to a low of $270000.0 in Q1 2021.
  • A 5-year average of $1.1 million and a median of $1.3 million in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: decreased 19.34% in 2022, then skyrocketed 166.19% in 2023.
  • Xenon Pharmaceuticals' Current Leases stood at $605000.0 in 2021, then fell by 19.34% to $488000.0 in 2022, then surged by 166.19% to $1.3 million in 2023, then rose by 5.39% to $1.4 million in 2024, then grew by 11.91% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Current Leases are $1.5 million (Q4 2025), $1.5 million (Q3 2025), and $1.5 million (Q2 2025).